MAP2K7 and cancer: Our data suggest that the use of MEK/ERK inhibitors may sensitise cancer cells to ER-stress, providing an opportunity to increase apoptosis by combining MEK/ERK inhibition with drugs that induce ER-stress, for example proteasome inhibitors or chaperone inhibitors [40].